Dynogen Research Operation Acquired by Astellas Pharma Inc.WALTHAM, Mass. & TOKYO -- Dynogen Pharmaceuticals, Inc. and Astellas Pharma, Inc. announced today that Astellas has acquired Dynogen's North Carolina-based research facility. Financial details regarding the sale were not disclosed. The research facility specializes in state-of-the-art preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. for genitourinary genitourinary /gen·i·to·uri·nary/ (jen?i-to-u´ri-nar-e) pertaining to the genital and urinary organs. gen·i·to·u·ri·nar·y adj. Abbr. disorders. "We've built an impressive clinical and preclinical pipeline through our unique understanding of the neuroscience underlying gastrointestinal and genitourinary disorders, leveraging that knowledge to generate strong intellectual property and utilizing that intellectual property to enable an aggressive in-licensing program," said Lee R. Brettman, M.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Dynogen. "We've maximized the value of the North Carolina North Carolina, state in the SE United States. It is bordered by the Atlantic Ocean (E), South Carolina and Georgia (S), Tennessee (W), and Virginia (N). Facts and Figures Area, 52,586 sq mi (136,198 sq km). Pop. facility in this effort, and now will focus all of our efforts on advancing the development of our five clinical programs and our late-stage preclinical programs." "Dynogen has built a facility with first-class capabilities for evaluating the clinical potential of urological development candidates especially in the area of lower urinary tract disorders. The acquisition of this research facility will strengthen our capabilities in this key area," said Isao Yanagisawa, Ph.D., Senior Corporate Officer of Astellas Pharma, Inc. About Dynogen Pharmaceuticals, Inc. Dynogen is a privately held, neuroscience-based pharmaceutical company developing more effective treatments for gastrointestinal and genitourinary and disorders. Today, Dynogen has three clinical development candidates, DDP (Distributed Data Processing) See distributed processing. DDP - Distributed Data Processing 200 for overactive bladder, DDP225 for irritable bowel syndrome irritable bowel syndrome (IBS), condition characterized by frequently alternating constipation and diarrhea in the absence of any disease process. It is usually accompanied by abdominal pain, especially in the lower left quadrant, bloating, and flatulence. with diarrhea (IBS-d) and chronic functional vomiting (CFV), and DDP733 for IBS IBS Irritable bowel syndrome, see there with constipation (IBS-c) and nocturnal gastroesophageal reflux disease gastroesophageal reflux disease (GERD) Disorder characterized by frequent passage of gastric contents from the stomach back into the esophagus. Symptoms of GERD may include heartburn, coughing, frequent clearing of the throat, and difficulty in swallowing. (n-GERD). More information about the Company can be found by visiting our website www.dynogen.com. About Astellas Pharma Inc. Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. In April 2005, the company was formed through the merger of Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. The organization is committed to becoming a global mega pharmaceutical company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. For more information on Astellas Pharma Inc., please visit the company's website at www.astellas.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion